Arrowpoint Investment Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Arrowpoint Investment Partners’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$328K	Buy	+9,829	New	+$244K	0.07%	86

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Arrowpoint Investment Partners's RARE Position: Q2 2026 in Review

Arrowpoint Investment Partners opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 9,829 shares worth $328K. The stake represents 0.07% of the portfolio and ranks #86 among its holdings.

310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Arrowpoint Investment Partners held 9,829 shares of Ultragenyx Pharmaceutical worth $328K as of Q2 2026.
Ultragenyx Pharmaceutical was a new Arrowpoint Investment Partners position in Q2 2026.
Ultragenyx Pharmaceutical made up 0.07% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #86 holding.
310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.